A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed
to evaluate the efficacy, safety, and tolerability of huMAb OX40L administered to patients by
IV infusion for the treatment of allergen-induced asthma.